Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 50, 2020 - Issue 4
Submit an article Journal homepage
252
Views
0
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study

F. ColomboH3 Biomedicine, Cambridge, MA, USA;
,
S. SmithH3 Biomedicine, Cambridge, MA, USA; ;Relay Therapeutics, Cambridge, MA, USA;
,
G. W. LaiEisai, Andover, MA, USA;
,
D. NixIDD, Certara Strategic Consulting, Princeton, NJ, USA
,
P. G. SmithH3 Biomedicine, Cambridge, MA, USA;
,
J. SchindlerH3 Biomedicine, Cambridge, MA, USA;
&
N. RiouxIDD, Certara Strategic Consulting, Princeton, NJ, USACorrespondence[email protected]
 show all
Pages 458-467 | Received 29 May 2019, Accepted 11 Jul 2019, Published online: 02 Aug 2019

References

  • Awasthi YC, Sharma R, Singhal SS. (1994). Human Glutathione S-transferases. Int J Biochem 26:295–308.
  • Baillie TA. (2016). Targeted covalent inhibitors for drug design. Angew Chem Int Ed 55:13408–21.
  • Bhattacharjee P, Paul S, Banerjee M, et al. (2013). Functional compensation of glutathione S-transferase M1 (GSTM1) null by another GST superfamily member, GSTM2. Sci Rep 3:2704.
  • Board P, Coggan M, Johnston P, et al. (1990). Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther 48:357–69.
  • Dickinson PA, Cantarini MV, Collier J, et al. (2016). Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 44:1201–12.
  • FDA. (2019). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm [last accessed 23 Apr 2019].
  • French DM, Lin BC, Wang M, et al. (2012). Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7:e36713.
  • GBD 2013 Mortality and Causes of Death Collaborators (2015). Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–71.
  • Jones S. (2008). Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 5:42–8.
  • Joshi JJ, Coffey H, Corcoran E, et al. (2017). H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma. Cancer Res 77:6999–7013.
  • Llovet JM, Ricci S, Mazzaferro V, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–90.
  • Meister A. (1988). Glutathione metabolism and its selective modification. J Biol Chem 263:17205–8.
  • Pinyol R, Nault JC, Quetglas IM, et al. (2014). Molecular profiling of liver tumors: classification and clinical translation for decision making. Semin Liver Dis 34:363–75.
  • Rioux N, Kim A, Nix D, et al. (2019). Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers. Cancer Chemother Pharmacol 83:91–6.
  • Scheers E, Leclercq L, de Jong J, et al. (2014). Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos 43:289–97.
  • Shibata Y, Chiba M. (2015). The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib. Drug Metab Dispos 43:375–84.
  • Stopfer P, Marzin K, Narjes H, et al. (2012). Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69:1051–61.
  • Takenaka K, Morgan JA, Scheffer GL, et al. (2007). Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67:6965–72.
  • Tate SS, Meister A. (1981). gamma-Glutamyl transpeptidase: catalytic, structural and functional aspects. Mol Cell Biochem 39:357–68.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.